Coxsackievirus B serotype 6 antigens (CV-B6 antigens)

Coxsackievirus B serotype 6 (CV-B6) antigens refer to the structural and non-structural proteins of this specific enterovirus, a member of the Picornaviridae family (Source: ICTV, NCBI Taxonomy). The viral capsid is composed of four structural proteins (VP1, VP2, VP3, and VP4), which are the primary targets for the host's immune system and are essential for binding to the Coxsackievirus and Adenovirus Receptor (CAR) to facilitate cell entry (Source: PubMed, PMID: 28254971). CV-B6 is associated with a range of clinical manifestations, including aseptic meningitis, pleurodynia, and inflammatory heart diseases such as myocarditis and pericarditis (Source: StatPearls, Enteroviruses). In therapeutic development, these antigens are utilized in the design of multivalent vaccines intended to provide broad protection against the six Coxsackievirus B serotypes (Source: ClinicalTrials.gov). While no specific antiviral is currently approved for CV-B6, experimental drugs like pleconaril target the VP1 antigen to block viral uncoating, and protease inhibitors target non-structural antigens like the 3C protease to halt viral replication (Source: Journal of Virology). Understanding the antigenic profile of CV-B6 is critical for both diagnostic serology and the development of targeted prophylactic interventions.

Other names

CVB6 antigensCoxsackievirus B6 viral proteinsEnterovirus B serotype 6 antigensCV-B6 capsid proteins

Vaccines targeting these antigens induce neutralizing antibodies that bind to the viral capsid, preventing attachment to host receptors like the Coxsackievirus and Adenovirus Receptor (CAR). Antiviral compounds such as capsid binders (e.g., pleconaril) interact with the hydrophobic pocket of the VP1 protein to inhibit viral uncoating and RNA release.